At a glance

SS-31 Quick Reference

Community Range: Members only
Sign in to view dosing details.
Cycle: Members only
Sign in to view dosing details.
Approved Use: Barth Syndrome
Forzinity for patients weighing at least 30kg
Primary Target: Cardiolipin
Inner mitochondrial membrane

Overview

What Is SS-31?

SS-31 is a synthetic tetrapeptide that selectively targets the inner mitochondrial membrane, where cells generate most of their usable energy. Its technical name is elamipretide, and it was developed by Dr. Hazel Szeto at Weill Cornell Medical College and Dr. Peter Schiller at the Montreal Clinical Research Institute. The name SS-31 stands for Szeto-Schiller peptide 31.

That repair-first mechanism separates SS-31 from compounds intended primarily to increase metabolic signaling or supply cellular fuel. Research has explored elamipretide across mitochondrial disease, skeletal muscle function, cardiovascular performance, kidney disease, aging, and recovery, with the strongest regulatory validation coming from its approved use in Barth syndrome.

Community interest is strongest among adults dealing with declining energy, slower recovery, metabolic strain, or other signs of accumulated mitochondrial stress. Younger, metabolically healthy users may notice less.

Age-Related Decline: A repair-focused approach becomes more relevant as mitochondrial efficiency and resilience decline with age. Slow Recovery: Users often pursue SS-31 when training recovery, exercise tolerance, and baseline energy begin to slip. Metabolic Strain: SS-31 may be relevant when mitochondrial stress is part of a broader metabolic or energy-production problem. Poor Response to NAD+ or MOTS-c: Some community users explore SS-31 when NAD+ or MOTS-c produces little noticeable benefit, although this sequence has not been validated clinically.

Mechanism

SS-31 Mechanism of Action

Cardiolipin Binding

SS-31 targets cardiolipin, a lipid in the inner mitochondrial membrane that supports its folded structure and energy-producing machinery. This places SS-31 at the membrane itself, where it can influence mitochondrial function.

Membrane Stability & ATP Production

In preclinical studies, SS-31 protects cristae—the membrane’s internal folds—and supports electron transport. Preserving this structure helps existing mitochondria produce ATP more efficiently, rather than simply increasing mitochondrial numbers.

Reduced Oxidative Damage

SS-31 inhibits the damaging peroxidase activity of the cytochrome c–cardiolipin complex while preserving cytochrome c’s electron-carrying role. This helps limit cardiolipin oxidation and protect membrane function under cellular stress in experimental models.

Calcium Stress Regulation

In laboratory studies, SS-31 changes the electrical properties of the mitochondrial membrane surface and how calcium interacts with it. This reduces the energetic burden of calcium stress, adding another route for protecting mitochondrial function.

Research findings

SS-31 Benefits

Mitochondrial Repair

SS-31 is about mitochondrial quality, not quantity. Research in aged animals showed improved morphology, restored cristae structure, and reduced markers of cellular senescence.

Improved Energy Production

By stabilizing the electron transport chain and reducing electron leakage, SS-31 can improve ATP output from existing mitochondria.

Reduced Oxidative Stress

SS-31 reduces mitochondrial reactive oxygen species production at the source by protecting cardiolipin and membrane function.

Organ Protection

Heart, kidney, brain, and skeletal muscle are highly dependent on mitochondrial function and are common targets in SS-31 research.

Functional Aging Support

Preclinical aging research suggests potential improvements in frailty, cardiac strain, skeletal muscle fatigue resistance, and inflammatory signaling.

Exercise Capacity

In Barth syndrome research, elamipretide was associated with meaningful improvements in functional measures such as walking capacity.

Protocol planning

SS-31 Dosing Protocol

Members Access Only

Sign in or create a free account to view this content.

Preparation

SS-31 Reconstitution

Reconstitution Example

10mg vial + 2mL bacteriostatic saline

Concentration5mg/mL

Reconstitution steps

1

Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2

Add diluent slowly

Use a new sterile syringe and needle to add 2mL of your selected diluent down the inside wall of the 10mg vial.

3

Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake. Discard material that is cloudy, discolored, gel-like, or contains visible particles.

4

Storage

Refrigerate after reconstitution and protect from light. Record the reconstitution date in your research journal.

N=1 Reports

SS-31 Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Improved daily energy is commonly reported after the initial adjustment period.
The energy effect is usually described as steady and functional rather than stimulant-like.
Smoother training recovery and better exercise tolerance are recurring themes.
Some users report less screen-related eye strain during a cycle.
NAD+ or MOTS-c may feel more noticeable after an SS-31 phase for some users.

Negative Reports

Injection-site redness, itching, pain, and welts are among the most common complaints.
An initial bout of fatigue is reported by some users before energy improves.
Some users find the effects too subtle to separate from normal day-to-day variation.
Nonresponse occurs, and perceived benefits vary widely.
Headache or gastrointestinal discomfort is occasionally mentioned.

Stacking & synergy

SS-31 Stacking & Synergy

SS-31 + NAD+

SS-31 supports mitochondrial structure, while NAD+ supports the reactions that turn nutrients into cellular energy. Our preferred sequence is SS-31 first, then NAD+—repair the machinery before supporting its energy pathways.

SS-31 + MOTS-c

SS-31 acts at the inner membrane through cardiolipin stabilization. In preclinical research, MOTS-c supports mitochondrial efficiency through AMPK/PGC-1α and stress defenses involving NRF2. These offer complementary routes to limiting oxidative stress; our preferred approach is to overlap them.

SS-31 + GLP-1 Agonists

In body-composition protocols, tirzepatide or retatrutide addresses appetite and glucose regulation, while SS-31 targets mitochondrial function. The rationale is to pair reduced calorie intake with support for cellular energy production.

Safety notes

SS-31 Side Effects & Safety

Across clinical research, elamipretide has shown a generally favorable safety profile. Injection-site reactions are the most consistently reported adverse effects.

Common or Expected

Injection-site redness.
Injection-site itching or irritation.
Localized pain or tenderness.
Temporary fatigue or headache.

Less Common or Important

Hives or urticaria.
Persistent local swelling or significant irritation.
GI discomfort.
Potential complications in people with impaired kidney function.

Contraindications and Precautions

Avoid Use With

Known hypersensitivity to SS-31, elamipretide, or formulation components.
Pregnancy or breastfeeding: human safety data are insufficient.
Rotate injection sites. Seek assessment before continuing if reactions are persistent or severe.

Use Caution With

Kidney impairment. Elamipretide and its metabolites are cleared through the kidneys. The approved dose is reduced for severe impairment (eGFR below 30mL/min/1.73m²) without dialysis; dialysis dosing is not established.
Other conditions or medications. Review heart or autoimmune conditions and medications affecting mitochondrial function with your doctor. Specific SS-31 interactions are not established.
Drug Interactions. No well-established drug interactions. Do not mix the approved product with other medications in the same syringe.

Final verdict

Peptide Protocols Verdict on SS-31

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Our opinionated opinion

SS-31 is one of the strongest mitochondrial peptides we have tested. It targets cardiolipin in the inner mitochondrial membrane, helping stabilize membrane function, reduce excess reactive oxygen species, and improve electron-transport-chain efficiency. The practical result is better cellular energy production, especially under stress.

We have experimented with the protocol above, and the results were clean and noticeable: improved daily energy after an initial bout of fatigue, less screen-related eye strain, and smoother recovery. It does not produce flashy overnight changes, but it delivers a reliable functional upgrade that builds over time.

The injections were manageable, although welts were common with bacteriostatic water. Switching to bacteriostatic saline substantially reduced those reactions for our lab rats. For age-related decline, SS-31 is one of the few compounds we would seriously consider revisiting as part of an annual routine. It earns its assigned grade through a strong mechanism, meaningful real-world utility, and favorable human tolerability.